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INTRODUCTION 
Change control is the most critical element in a 
pharmaceutical or biotech company's quality management 
system - inadequate change control procedures end up 
creating a huge risk of non-compliance. The FDA's 
guidance for Industry clearly reinforces the importance of 
implementing an effective change control procedures as a 
critical component in an overall quality system - see 
"Quality Systems Approach to Pharmaceutical Current 
Good Manufacturing Practice Regulations (CGMP)". It's 
important for FDA-regulated companies to be able to 
implement a quality system that automates change 
management and change control procedures and ensures 
that they are in compliance with GxPs and 21 CFR Part 11. 
INITIATIVES TO CHANGE 
Change control is a formal process used to ensure that 
changes to a product or system are introduced in a 
controlled and coordinated manner. The goals of a change 
control procedure usually include minimal disruption to 
services, reduction in back-out activities, and cost-
effective utilization of resources involved in implementing 
change. It would be very difficult to carefully manage 
change control in a large company or a fast growing 
organization without an enterprise-wide change control 
system One of the most important aspects of change 
control is to maintain a history of changes for audit trail 
purposes - a capability better facilitated by such systems. 
ESSENTIAL REQUIREMENTS OF CHANGE 
CONTROL SYSTEM 
The change control system requires a structured approach 
towards managing change in an environment focused on 
continuous improvement. The system must manage the 
end-to-end change control process including initiating, 
reviewing, approving, distributing and storing change 
history. Such a system can provide evidence of compliance 
to FDA. In addition, the system should also help capture 
relevant information about the objective, nature and scope 
of change. The scope of the change control program must 
also cover a broad set of possibilities including changes to 
product formulation or design, upgrades to facilities, 
utilities, equipment and computer systems, manufacturing 
instructions, SOPs, test methods and specifications, any 
new raw materials as well as any changes in policy. 
Change control system maintains a history of the lifecycle 
of all change requests. Such information is used by FDA 
during audits to ensure change control procedures are 
working well and facilitates regulatory filings and prior 
regulatory approval. Best practices and industry standards, 
as well as regulations imposed by regulatory bodies, 
require companies to demonstrate control over change 
management. Change control systems must ensure 
consistent procedures and informed decision-making by 
qualified individuals as well as assure traceability back to 
the justifications behind the change process. 
BENEFITS OF CHANGE CONTROL SYSTEM 
 Careful planning helps to ensure that the change 
process is started and managed by the right people at 
the right time 
 Planned change management allows us to include 
specific tasks and events that are appropriate for each 
stage in the change process 
 Change management ensures that customers, 
suppliers and other stakeholders understand and 
support the change 
 Change control reduces disruptive aspects and 
emphasizes positive opportunities in the change 
process 
 Change control allows easy tracking of changes and 
compliance to FDA regulations. 
 
ABSTRACT- 
The change control is ―A process that ensures that changes to materials; methods, equipment and software are properly 
documented, validated, approved and traceable‖. The process requires eight basic steps: Identification, documentation review, 
change proposal, change classification, implementation plan, installation, verification, closure. Changes are outlines as Major, 
Moderate & Minor. A compliance of regulatory group within the company determines the filing impact and submits it to FDA,-A 
prior- Approval supplement (PAS) for major changes, A CBE -30 or CBE-0 for moderate changes or Annual report for Minor 
changes. Firms are expected to write adequate Standard Operating Procedure (SOP) for the change control & be in total 
compliance with proper documentation. Considering the regulatory prospective of change control procedures, it is important to 
note that there are many guideline which describe the control of changes in manufacturing few references includes 21 CFR Part 
211: Sec. 211.100, 21 CFR Part 211.194 (Laboratory Records), ICH Q7A and USFDA Guidance for Industry:  Change to an 
approved NDA or ANDA (April 2004- Revison-1). 
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Overall, companies can see improved benefits for all their 
stakeholders including QA/QC managers, regulatory 
affairs specialists, documentation managers, production 
specialists, facility managers and engineers, 
operations/maintenance specialists, compliance auditors 
and R&D tech transfer managers. The benefits are accrued 
across the extended enterprise. The system also ensures 
continued compliance with regulations.1, 3, 4 
MANAGEMENT OF CHANGE AND CONTINUOUS 
IMPROVEMENT 
Changes to process, equipment, procedures, technology, 
material and organization are necessary for continuous 
improvement and a MOC system must also be 
continuously improved. The process requires eight basic 
steps: 
 Identification  
 Documentation review  
 Change proposal  
 Change classification  
 Implementation plan  
 Installation  
 Verification  
 Closure  
 
Applying these steps, the system can be designed for 
managing the configuration and controlling the change, 
and then the necessary procedures and forms can be 
prepared. It is important that the system design come first. 
Specifically: 
 Identify the change to be made  
 Accumulate and review the baseline documentation, 
including drawings, procedures, P&IDs, equipment 
data sheets and MOC forms.  
 
Prepare a Change Proposal 
The change proposal is the vehicle used to document the 
changes in the specific application area. It is assigned a 
change proposal number, identifies approval authority, 
defines security, and establishes issued date, effective date, 
and distribution. The baseline configuration and 
documentation are verified. From this point on, the change 
proposal must be controlled throughout the lifecycle. 
Classify & Approve Proposed Changes 
The Change Control Board must review, evaluate, and 
approve changes and then classify the change as normal, 
urgent, emergency, or temporary. In some cases, changes 
which are low-risk and low-cost may be approved by the 
Configuration Manager. 
Develop an Implementation Plan 
The implementation plan describes how the change will be 
put in place. Baseline documentation is updated. Operators 
and maintenance personnel are trained in the change. 
Install the Change 
This step speaks for itself. 
 
 
 
Verify Installation 
Track the status of the change. Verify that each step in the 
process is completed and the documentation matches the 
―as-built‖ configuration. Conduct a system audit. 
Close Out the Change 
Everything is completed and the cycle is repeated for the 
next proposed change. Managing change requires that the 
purpose and justification of the change be documented; 
change be reviewed for impact on safety, health and 
environment; cGMPs be reviewed for impact on GMP 
values; additional risk is not introduced into the process; 
authorization be documented; process information be 
updated; operating and maintenance procedures be revised; 
personnel who are affected by the change be trained; and 
configuration of the plant be maintained. 
Sometimes changes can introduce new hazards or 
compromise safeguards built into the design of a process. 
Situations may occur that require an immediate change to 
protect the health and safety of the employees, facility or 
community. Immediate changes should have their own 
procedures that list steps to be taken and requirements.2, 3, 
4,5,6,7 
STANDARD OPERATION PROCEDURE 
The purpose of a Standard Operation Procedure is to 
ensure that all changes related to any aspect of 
manufacture, testing, holding and distribution are assessed 
and consequently addressed for their impact on the 
identity, strength, quality, and purity of the drug product 
including the assessment of the qualification and validation 
status and the regulatory situation. 
Table of content 
1. Responsibilities 
1.1 Applicant 
1.2 System Owner 
1.3 Quality Department 
2. Purpose/Aim 
3. Scope 
4. Definitions & Abbreviations 
4.1 Like for like replacements / changes 
4.2 Temporary and Permanent Changes 54 
5. Procedures 
5.1 Raising a Change Control Form 
5.2Implementation of Change 
5.3 Final Review and Close Out 
6. Distribution 
 
Deviations (Failure Investigations, Non-Conformances)  
The purpose of this procedure is to ensure that all 
Deviations are: Investigated within 30 working days, all 
investigations are completely documented, assessed by the 
responsible line units and QA, corrective actions if 
applicable are implemented and implementation is tracked, 
the complete process is managed, monitored and 
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controlled. 
1. Regulatory Basis, Reference Documents 
2.Responsibilities and Accountabilities 
3.Purpose / Aim 
4.Scope 
5.Definitions & Abbreviations 
5.1. Deviation 
5.2 Incident (minor deviation) 
5.3 Investigation 
5.4.Immediate Action 
5.5.Corrective Actions 
5.6.Preventative Action 
5.7 Trending 
6. Procedure (course of events) 
7.Distribution 
8. Attachment (form) 
 
 
 
Figure 1: Flow Chart of Change Management System 
Handing of OOS Results 
FDA considers the integrity of laboratory testing 
documentation records to be of fundamental importance 
during drug manufacturing. As a drug manufacturer you 
have to assure that your laboratory investigation in cases of 
failures (OOS results and confirmed OOS results) is done 
without compromising products quality or current 
authority expectations. This SOP (13 pages plus 
attachment) guides you step by step through the process of 
investigating and documenting OOS results. It describes 
the responsibilities of laboratory personnel, the QC 
supervisors and QA Managers. Attached to the SOP is an 
easy understandable from reflecting the OOS process 
where you put the relevant data and assessments in three 
logical sections, the Preliminary Assessment, Investigation 
Plan and Results and the Final Approval. This SOP only 
needs little site-specific modification before you can adopt 
this SOP to your operations.  
1. Regulatory Basis, Reference Documents 21 CFR 
211.165, 21 CFR 211.160, 21 CFR 211.192, FDA Draft 
Guideline ―Investigating Out of Specification (OOS) Test 
Results for Pharmaceutical Production 
2. Purpose / Aim 
3.  Scope 
4.Responsibilities and Accountabilities 
4.1 Analyst 
4.2 Supervisor 
4.3 Quality assurance 
5. Procedure 
5.1 Laboratory investigation – guiding principles 
5.1.1Retesting  
5.1.2 Re-sampling  
5.1.3 Averaging  
5.1.4 Outlier tests 
5.2 Conclusion of the investigation 
5.2.1 Interpretation of results 
5.2.2 Reporting and documentation  
5.2.2.1 Reporting  
5.2.2.2 Documentation 
6. Definitions & Abbreviations defined. 
7. Distribution 
8. Attachment (4 pages) 
· Section I Preliminary Assessment 
· Section II Investigation Plan and Results 
· Section III Final Approval 
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GMP - STANDARD OPERATING PROCEDURES 
(SOP) 
Investigation of Complaints 
Insufficient customer complaint handling was and still is 
one of FDAs top findings in the published warning letters 
under FDAs Freedom of Information. In addition FDA 
starts to review not only US related customer complaints 
for products on the US market but since the New Quality 
System Approach is used during inspections also 
complaints for non US – products may be investigated to 
challenge the companies complaint system. This SOP 
including a investigation form attached guides you step by 
step through the process of investigating, documenting, 
reporting and follow up customer complaints. Also the 
responsibilities for the complaint investigations are clearly 
defined, which is a crucial prerequisite for any functional 
system. This SOP only needs little site-specific 
modification before you can adopt this SOP to your 
operations. 
1. Regulatory Basis, Reference Documents 
2. Purpose 
3. Scope 
4. Complaint categories 
4.1 Commercial Complaints 
4.2 Product Technical Complaints (PTC) 
4.3 Adverse Drug Event (ADE) Complaints 
5. Responsibilities and Accountabilities 
5.1 Quality Assurance 
4.1.1 Complaint information 
4.1.2 Complaint registration 
4.1.3 Internal Notification 
4.1.4 Complaint Tracking and follow up 
4.1.5 Complaint final decision 
4.1.6 Complaint response 
4.1.7 Document complaint compiling and retention 
4.1.8 Complaint Samples storage and retention 
4.1.9 Complaint Trending 
5.2 Quality control 
5.2.1 Test of complaint samples 
5.2.2 Reserve Samples 
5.2.3 Report of test results 
5. Complaint Investigation 
6. Definitions & Abbreviations 
7. Distribution8, 9 
CATEGORY OF CHANGES 
Impact assessment of changes is extremely important to 
the agency & changes are outlines as Major, Moderate & 
Minor. A compliance of regulatory group within the 
company determines the filing impact and submits it to 
FDA,- 
 A prior- Approval supplement (PAS) for major 
changes,  
 A CBE -30 or CBE-0 for moderate changes or  
 Annual report for Minor changes. 
Major Changes- 
 Is likely to have a detectable impact on the critical 
attributes of the product, significantly. 
 Could shift the process in a discernible manner ( 
Such as: quality, yield, stability, impurity profile, 
crystal form, particle size, bulk density) 
 Warrants definite additional/ major testing & suitable 
revalidation studies to justify changes. 
 Reviewed by QA at the facility level & approved by 
corporate groups. 
 Requires prior FDA approval. 
Few examples of Major Changes- 
 Change in type of solvent used for final 
crystallization ( affects impurities profile, physical 
attributes & other critical quality attributes of API) 
 Change in equipment type ( Dryer, configuration, 
Blender type, crystallizer type, tablet compression 
machine, coating equipment) 
 Change in critical process parameters. 
 Revision of critical quality attributes (specifications), 
such as assay limit, dissolution profile, related 
substance test. 
 Related substance limit. 
 Revision of standard test procedure for assay 
(potentiometric to HPLC) for related substance ( 
TLC to HPLC), for residual solvents (GC to Head 
space) 
 Change in facility (site of manufacturing ) 
 Change in batch size by more than 10% 
 Change in route of synthesis 
 Change in isolators, RABS or C-RABS systems. 
Change in API source. 
 Change in validation sterilization process. 
 Change in sequence of operations.  
Moderate changes- 
 Is usually for improvements to process, materials, 
product or procedure 
 Therefore, no reason to wait for approval 
 Does not require prior approval by regulatory /FDA 
before implementation 
 The agency will want to review it 
 Can go in annual report to FDA  
 Can be evaluated by QA, at the facility & then 
approved by corporate groups. 
 These are called ― change being effected‖  
 Categories are CBE-30 & CBE-0 
Few examples of moderate changes- 
 Improvement in yield 
 Improvement in critical quality 
 Improvement in attributes  
 Improvement in process capability/efficiency 
 Cost- effectiveness 
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Figure 2: Change work flow task from initiation to closure from traceable authenticity 
Minor changes 
 Is unlikely to have a detectable impact on the critical 
attributes of the products. 
 Does not shift the process in any discernible manner 
 Can be implemented with minimal testing and 
revalidation 
 Can be reviewed and approved by QA at the facility 
level 
 Is reported  in annual reports to FDA and does not 
require FDA approval 
Few examples of minor changes 
 Like for like equipment replacement 
 Noncritical process parameter 
 Revision for specifications (such as noncritical 
parameters) as per process capability. 
 Revised quality of components and reagents, 
marginally in case of API intermediates 
 Revised operating procedure to add safety 
 Revised cleansing procedure to enhance GMPs 
 Editorial changes10,11,12,13,14,15,16 
Scientific judgment should determine what additional 
testing & validation studies are needed to justify a change 
in a validation process. 
In the future, the comparability protocols will be required 
to support and justify the changes. This will improve the 
approval timing for the agency and also will reduce the 
risk of having an adverse affect on the SQIPP o f the 
product. This requirement will also ensure that no 
adulterated product ever gets released. Comparability 
protocols will be a submission to the agency and, as such, 
any change to the protocols must go through the change 
control process. 
When developing a change control procedure, following 
points must be considered 
Sharma et al                                     Journal of Drug Delivery & Therapeutics; 2011, 1(1): 24-31   29 
© 2011, JDDT. All Rights Reserved 
 Developing a robust change control system 
 Educate users of the change control system, and 
 Enforce change control system policies and 
procedures 
A change control policy must be in place with supporting 
SOPs and a Process Map that will guide users through the 
process so as not to deviate or work outside of the process. 
Stakeholder Matrix is also important so that it will provide 
guidance on the distribution for assessment of impact. The 
process must be user friendly and efficient or it will be 
unacceptable to the users. After a robust manual process 
been developed and implemented it must be owned by the 
Quality Organization as it is a part of compliance 
requirements. 
Figure 3: Change workflow task from initiation to closure with traceable authenticity 
All the document s should be complete, accurate, detailed, 
unambiguous, credible, verifiable, and defendable and 
supported by scientific evidence, as they will be accessed 
by Federal Regulators. It is also important to make sure a 
tracking system in place so that document can be located 
and retrieved at any time. 
It is important to understand not only the type of changes 
that will be a part of change control process, but also the 
priority of those changes. Change should never be 
expedited, but should either planned or unplanned. Almost 
all changes can be planned; only those that are 
emergencies occurring after hours, on weekends, or are 
safety-related should be considered as unplanned. in all 
cases they should be submitted through change control and 
any required validation / revalidation must be completed 
before the change is fully implemented.10 
ENSURING TRAINING AND PROCEDURES IN A 
MANAGEMENT OF CHANGE PROGRAM 
A large part of Management of Change is maintaining up-
to-date documentation. Situations occur where personnel 
are not aware of changes to documentation that could 
indicate training does not keep pace with changes in job 
functions. Typical problems include not being aware of 
changes in training or procedures, not maintaining up-to 
date documentation, and lack of a detailed procedure that 
describes the MOC process. 
In order to eliminate these problems, corrective or 
preventive actions may be necessary, such as: auditing the 
training program and/or the procedure program for 
deficiencies; making training part of the MOC program; 
developing a detailed procedure that describes a process 
for initiation, review and approval; and documentation, 
training in change, and implementation of any changes. 
The lack of agreement between training and procedures is 
a major industry problem, especially in a regulated 
environment. The question becomes which is correct — 
the training or the procedure? 
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Training in change is required for all changes in process 
and operation; technology; facilities and equipment; and 
procedures. It may be as simple as reading and initialing 
simple changes in a procedure if it does not affect skills or 
knowledge. In other cases, it could require developing new 
lesson plans to teach the new skills and knowledge, or 
developing and delivering structured on-the-job training. 
Reinforcement training, an FDA requirement, is targeted 
for performers to maintain their skills and knowledge. 
Training in change should be critical and may cover much 
of the reinforcement training.7 
LEVEL OF APPROVAL- 
The change control proposals are formal documents and 
must be initiated by the affected group. For eg production 
unit is the effected group for changes to equipment and 
facility expansion. in this eg, production unit will initiate 
the change proposal .This proposal could reviewed and 
discussed by other responsible persons from departments, 
such as R & D ,QA ,Regulatory  and affected client. 
However, the final approval is granted by Quality Unit. It 
is important to assign levels of approval within 
departments .for changes categorized as Major, the review 
and approval must be dealt with by senior experts from 
stakeholder department and Quality Unit. in contrast ,for 
the change categorized as Minor, the review and approvals 
can be delegated to trained personnel who are not 
necessarily from senior management. 
Once a manual process has been implemented, one of the 
stakeholder groups such as Regulatory needs to conduct an 
internal audit once a year. Based upon business needs, it 
may be necessary to automate the process with validated 
software. if process is not working well, this software 
should not be purchased to fix the problems. it will only 
waste of time and will make the situation worse. in order 
to find the software that will fit the process; a functional 
requirement specification outlining what is expected of the 
program should be written. From there, a matrix is used to 
evaluate the right software for correct environment. 
When all of the pieces, are in place, change control process 
/program will provide the ability to submit, evaluate, 
approve, communicate, correctly implement and document 
all change that impact SQIPP. 
HANDLING AND CONTROLLING CHANGES- 
Handling and controlling change initiator call for a 
meeting of change control team and puts the proposal for 
change with the problems and consequences and 
advantages. 
Team reviews through Brainstorming session- 
Should the change be allowed?                            
Partly or Wholly? 
Regulatory impact? 
GMP & safety  impact? 
Need for requalification or revalidation? 
Customer/ Agency to be informed? 
Category of the change? Reporting category? 
Documentation requires & documents affected? 
If the team has decided on above points, the CCIF (change 
control initiation form) is processed by the team members 
for a sign-off & each member understands her/his 
responsibilities .the initiator coordinates the change 
process at all levels.QA checks the adequacy of the 
process data, impact and follow up closure and 
communicates to the customers/clients and management. 
Regulatory prepares the reporting document for the 
agency. 
REGULATOR PROSPECTIVE OF CHANGE 
CONTROL 
Considering the regulatory prospective of change control 
procedures, it is important to note that there are many 
guideline which describe the control of changes in 
manufacturing few references includes 
21 CFR Part 211: Sec. 211.100 
There shall be written procedure for production and 
process control designed to ensure that the drug product 
have the identity, strength, quality and purity. They purport 
or are represents to process. 
These written procedure, including any changes, shall we 
drafted, reviewed, and appointed by the appropriate 
organizational units & reviewed & approved by the quality 
control unit. 
21 CFR Part 211.194 (Laboratory Records) 
Complete record shall be maintained of any modification 
of an established method employed in testing. Such 
records shall include the reason for the modification & 
data to be verify that the modification produced results that 
are at least as accurate & reliable for the material being 
tested as established method. 
ICH Q7A 
A formal change control system should be established to 
evaluate all changes that could affect the production & 
control of the intermediate or API. Written procedures 
should provide for the identification, documentation, 
appropriate review, & approval of changes in raw 
materials, specifications, analytical methods, facilities, 
support systems, equipment, processing steps, labeling & 
packaging materials & computer software. 
USFDA Guidance for Industry:  Change to an 
approved NDA or ANDA ( April 2004- Revison-1) 
This guidance provides recommendations to holders of 
new drug applications (NDAs) & ANDAs who intend to 
make post approval changes in accordance with section 
506A of federal Food, Drug & Cosmetic Act ( the act) & 
$314.70 (21 CFR 314.70) The guidance covers 
recommended reporting categories for post approval 
changes for drugs other than specific biotechnology & 
specified synthetic biological products.10, 17, 18 
CONCLUSION 
Change is inevitable, and because continuous improvement 
is impossible without change, progress is built on change. 
The key to making successful change in the 
pharmaceutical world is to manage it, both from internal 
and external perspectives. Changes can happen at any time 
during a product’s lifecycle. The impact of the change 
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needs to be balanced against the cost of making the change 
(safety, time and money). Impact of change may require 
amendments to registered details. Changes must be 
formally documented and approved via a change control 
process. It needs to evaluate risk assessments throughout 
change control process. 
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